Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Understand the key aspects of points and cash back rewards. Equip yourself with knowledge to maximize your benefits.
28,655 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Tesla delivered 480,126 vehicles in Q2 2026, topping estimates by 74,000 and signaling a rebound in EV demand. The fo...
Richard Branson is pushing back on the idea that waking up at 5 a.m. guarantees success. He argues a sustainable rout...
As the ECB moves the digital euro from concept to pilot, it places a concrete €1.3B price on the project and faces le...
A new wave of tariff talk harkens back to a controversial era. This piece explains why trump’s tariffs: lesson econom...
A biotech stock that sprinted 685% in months drew a sizeable institutional bet as it pressed ahead with two FDA filin...
The federal debt breached $39 trillion this week as lawmakers debated a constitutional fix that failed to pass. The p...
Investors brace for potential disruption as Trump-Iran brinkmanship over the Strait of Hormuz raises the risk of oil ...
Investors are watching IonQ as it edges toward scalable quantum systems through a photonic interconnect. This breakth...
Investors are reallocating spending toward resale, repair, and value brands. Six ETFs are positioned to ride the circ...
Nvidia has acquired Kumo AI, adding enterprise-focused foundation models to its AI stack. Founders join Nvidia, with ...
Marvell Technology’s shares push higher on AI-driven demand, approaching a 200% year-to-date gain. Yet a blinking red...